Tanezumab: a selective humanized mAb for chronic lower back pain

Michael P Webb,1 Erik M Helander,2 Bethany L Menard,2 Richard D Urman,3 Alan D Kaye2 1Department of Anesthesiology, North Shore Hospital, Auckland, New Zealand; 2Department of Anesthesiology, LSU School of Medicine, New Orleans, LA, USA; 3Department of Anesthesiology, Perioperative and Pain Medicin...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Webb MP, Helander EM, Menard BL, Urman RD, Kaye AD
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Dove Medical Press 2018-02-01
Edice:	Therapeutics and Clinical Risk Management
Témata:	tanezumab monoclonal antibody chronic low back pain neurotrophin nerve growth factor (NGF) tropomyosin receptor A (TrkA) treatment
On-line přístup:	https://www.dovepress.com/tanezumab-a-selective-humanized-mab-for-chronic-lower-back-pain-peer-reviewed-article-TCRM
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!